Approvable letters, and the related non-approvable letters (alternately not-approvable letters), were notifications sent out by the Food and Drug Administration (FDA) to drug manufacturers alerting them to the approval prospects of their drugs under development.[1] The letters were intended to let manufacturers know how much work is needed on their applications.[1] Non-approval letters were rejections of a drug's application.[2] Approvable and non-approvable letters were covered under Title 21 of the Code of Federal Regulations, section 314.110.[3]
In 2018, the FDA replaced approvable letters with Complete Response Letters (CRL) to notify applicants when additional information is required before approval.[4][5]
YouTube Encyclopedic
-
1/3Views:1 968168 756687
-
Complete Response Letters Tutorial
-
How Does the FDA Approve a Drug?
-
Premarket Approval PMA Agreement with FDA for the Medical Device Companies
Transcription
Guidelines
Approvable letters were issued to applicants at the end of the FDA's review period to indicate that the application or abbreviated application is basically approvable providing certain issues are resolved. It was an indication that the application substantially met FDA requirements if specific conditions, such as labeling changes, are agreed to. The letter described what was required by the FDA.[3]
Applicants had 10 days after the date of the approvable letter to amend the application, notify of intent to file for an extension, withdraw the application, request a hearing or notify that they agreed to an extension.[3]
References
- ^ a b "F.D.A. Revises Its Letter for Nonapproval of Drugs". The New York Times. 2008-07-10. Retrieved 2018-09-28.
- ^ "FDA issues non-approvable letter for ISTA's T-Pred". ophthalmologytimes.com. 2007-05-05. Retrieved 2018-09-28.[permanent dead link]
- ^ a b c "Title 21 - Food and Drugs. CHAPTER I - FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED). SUBCHAPTER D - DRUGS FOR HUMAN USE. PART 314 - APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG. Subpart D - FDA Action on Applications and Abbreviated Applications". gpo.gov. 2006-04-01. Retrieved 2018-09-28.
- ^ "CFR - Code of Federal Regulations Title 21". fda.gov. 2018-04-01. Retrieved 2019-07-03.
- ^ "Complete Response Letter Final Rule". FDA. 9 February 2018. Retrieved 23 July 2019.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 5 September 2023, at 05:50